Nouvelles cibles pour les vaccins antibactériens

Revue Francaise des Laboratoires

Volumn 2000, Issue 326, 2000, Pages 53-60

  Choutet, Grégoire ^a   Andremont, Antoine ^b  

^a Laboratoire de Biologie Clinique   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Bacterial target; Bacterial vaccines; Acellular vaccines

Indexed keywords

EID: 0034288864     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0338-9898(00)80071-2     Document Type: Article

References (174)

1. Acharya I.L., Lowe C.U., Thapa R., Gurubacharya V.L., Shrestha M.B., Cadoz M. et al., Prevention of thyphoid in Nepal with the Vi capsular polysaccharide of Salmonella typhi, N. Engl. J. Med. 317 (18) (1987) 1101-1104.
2. ACIP, Update: Vaccine side effects, adverse reactions, contraindications and precautions, M.M.W.R. 45 (RR-12) (1996) 1-35.
3. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Brome C.V., Wenger J.D., Decline of chilhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine area, JAMA 269 (2) (1993) 221-226.
4. Aicardi T., Chevrie J.J., Accidents neurologiques consécutifs à la vaccination contre la coqueluche, Arch. Fr. Pediatr. 32 (4) (1975) 309-312.
5. Allaoui-Attarki K., Pecquet S., Fattal E., Couvreur P., Use of microspheres as delivery system to a obtain strong, diffuse and specific anti-phosphorytcholine mucosa immune response after oral immunization of BALB/c mice, Symposium on Mucosal Immunity, Capri, April 22-23th, 1994.
6. Allaoui-Attarki K., Pecquet S., Fattal E., Chachaty E., Couvreur P., Andremont A., Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-Lactide-co-glycolide) microspheres, Infect, Immun. 65 (3) (1997) 853-857.
7. Allaoui-Attarki K., Fattal E., Pecquet S., Trollé S., Chachaty E., Couvreur P., Andremont A., Mucosal Immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres, Vaccine 16 (7) (1998)665-691.
8. Alonso de Velasco E., Verheul A.F.M., Verhoef J., Snippe H., Streptococcus pneumoniae: Virulence factors, pathogenesis, and vaccines, Microbiol. Rev. 59(4) (1995)591-603.
9. Anderson E.L., Kennedy D.J., Gelmacher K.M., Donnelly J., Mendelman P.M., Immunogenicity of a heptavalent conjugated pneumococcal vaccine in infants. J. Pediatr. 128 (5) (1996) 649-653.
10. Andre F.E., Development and clinical application of new polyvalent combined paediatric, vaccines, Vaccine 17 (13-14) (1999) 1620-1627.
11. Anonymous, Global Programme for Vaccines and Immunization Vaccine Research and Development. Research priority 1997, Geneva: WHO/VRD.GEM 96.01 (1997).
12. Anonymous, Global Programme for Vaccines and Immunization Vaccine Research and Development. Research priority 1998, Geneva: WHO/VRD.GEM 97.01 (1998).
13. Anonymous, V&B Annual Report 1998, Geneva: WHO (1999).
14. Babiuk L.A., Broadening the approaches to developing more effective vaccines, Vaccine 17 (13-14) (1999) 1587-1595.
15. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hickman M.E., Kasper D.L., Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types la and lb, J. Infect. Dis. 179 (1) (1999) 142-150.
16. Barbour M.L., Conjugate vaccines and the carriage of Haemophilus influenzae type b, Emerg. Infect, Dis. 2 (3) (1996) 176-182.
17. Beckmann E., Lewitt D., Phosphorylcholine on Streptococcus pneumoniae R36a is responsible for a in vitro polyclonal antibody secretion by human peripheral blood lymphocytes, J. Immunol. 132 (5) (1984) 2174-2176.
18. Berche P., Choléra et environnement Med. Mal. Infect. 29(1999) 301-307.
19. Betts R.F., Treanor J.J., Approaches to improved influenza vaccination, Vaccine 1B (16) (2000) 1690-1695.
20. Beuvery E.C., van Rossum F., Nagel J., Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates, Infect. Immun. 37 (1) (1982) 15-22.
21. Bloom B.R., New approaches to vaccine development, Rev. Infect. Dis. 11 (Suppl. 2) (1989) S460-S466.
22. Blumberg D.A., Lewis K., Mink C.M., Christenson P.D., Chatfield P., Cherry J.D., Severe reactions associated with diphteria-tetanus-pertussis vaccine: Detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying, Pediatrics 91 (6) (1993) 1158-1165.
23. Booy R., Kroll J.S., Is Haemophilus influenzae finished?, J. Antimicrob. Chemother. 40 (2) (1997) 149-153.
24. Bowerman S.G., Green N.E., Mencio G.A., Decline of bone and joint infections attributable to Haemophilus influenzae type b, Clin. Orthop. 341 (1997) 128-133.
25. Briles D.E., Horowitz J., McDaniel L.S., Benjamin W.H., Claflin J.L., Booker C.L. et al., Genetic control of the susceptibility to pneurmococcal infection, Curr. Top. Microbiol. Immunol. 124 (1986) 103-120.
26. Briles D.E., Creech Tart R., Swiatlo E., Dillard J.P., Smith P., Benton K.A. et al., Pneumococcal diversity: Considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA), Clin. Microbiol. Rev. 11 (4) (1998) 645-657.
27. Briles E.B., Tomasz A., Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid, J. Biol. Chem. 248 (18) (1973) 6394-6397.
28. Bruyn G.A.W., van Furth R., Pneumococcal polysaccharide vaccines: Indications, efficacy and recommandations, Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 897-910.
29. Butler J.C., Shapiro E.D., Carlone G.M., Pneumococcal vaccines: History, current status, and future directions, Am. J. Med. 107 (1A) (1991)S69-S76.
30. Cadoz M., Guy B., Lissolo L., Rokbi B., Quentin-Millet M.J., Prespectives et difficultés du développement d'un vaccin contre Helicobacter pylori, Med. Ther. 6 (4) (2000) 319-323.
31. Cahill E.S., O'Hagan D.T., Illum L., Barnard A., Mills K., Redhead K., Immune responses and protection against Bordetella pertussis infection after nasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticules, Vaccine 13 (5) (1995) 455-462.
32. Cartwright K., Morris R., Rumke H., Fox A., Borrow R., Begg N. et al., immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins, Vaccine 17 (20-21) (1999) 2612-2619.
33. Challacombe S.J., Rahman D., Jeffery H., Davis S.S., O'Hagan D.T., Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen, Immunology 76 (1) (1992) 164-168.
34. Chang Y., Novosol V., McDonough S.P., Chang C.F., Jacobson R.H., Divers T. et al., Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses, Vaccine 18 (5-6) (1999) 540-548.
35. Cherry J.D., Comparative efficacity of acellular pertussis vaccines; an analysis of recent trials, Pediatr. Infect Dis. J. 16 (Suppl. 4) (1997) S90-S96.
36. Claflin J.L., George J., Dell C., Berry J., Patterns of mutations and selection in antibodies to the phosphorylcholin-specific determinant in Proteus morganii, J. Immunol. 143 (9) (1989) 3054-3063.
37. Cody C.L., Baraff L.J., Cherry J.D., Marcy S.M., Manclark C.R., Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children, Pediatrics 68 (5) (1981) 650-660.
38. Cohen D., Ashkenazi S., Green M., Lerman Y., Slepon R., Robin G, et al., Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers, Infect. Immun. 64 (10) (1996) 4074-4077.
39. Cohen D., Ashkenazi S., Green M., Gdalevich M., Robin G., Slepon R. et al., Double-blind vaccine-controlled randomised efficacity trial of an investigational Shigella sonnei conjugate vaccine in young adults, Lancet 349 (9046) (1997) 155-159.
40. Conlan J.W., Cox A.D., KuoLee R., Webb A., Perry M.B., Parenteral immunization with glycoconjugate vaccine containing the O157 antigen of Escherichia coli O157:H7 elicits a systemic humoral immune response in mice, but fails to prevent colonization by the pathogen, Can, J. Microbiol. 45 (4) (1999) 279-286.
41. Conlan J.W., KuoLee R., Webb A., Cox A.D., Perry M.B., Oral immunization of mice with a glycoconjugate vaccine containing the O157 antigen of Escherichia Coli O157:H7 admixed with cholera toxin fails to elicit protection against subsequent colonization by the pathogen, Can, J. Microbiol. 46 (3) (2000) 283-290.
42. Cowan M.J., Ammann A.J., Wara D.W., Howie V.M., Schultz L., Doyle N., Kaplan M., Pneumococcal polysaccharide immunization in infants and children, Pediatrics 62 (5) (1978) 721-727.
43. Cowan L.D., Griffin M.R., Howson C.P., Katz M., Johnston R.B., Slaywitz B.A., Fineberg H.V., Acute encephalopathy and chronic neurological damage after pertussis vaccine, Vaccine 11 (14) (1993) 1371-1379.
44. Crooy P., Lobet Y., An effective vaccine against Lyme disease, J. Biotechnol. 76 (2-3) (2000) 261-263.
45. Czinn S.J., Nedrud J.G., Working towards a Helicobacter pylori vaccine, Gastroenterology 116 (2) (1999) 990-993.
46. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O. et al., Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine, J. Infect. Dis. 174 (6) (1996) 1271-1278.
47. Dalseg R., Wedege E., Holst J., Haugen I.L., Holby E.A., Haneberg B., Outer membrane vesicles from group B meningococci are strongly immunegenie when given intranasally to mice, Vaccine 14 (17) (1999) 2336-2345.
48. de Kieijn, de Groot R., Labadie J., Lafeber A.B., van den Dobbelsteen G., van Alphen L. et al., Immunogenicity and safety of a hexavalent meningococcal outer-memorane-vesicle vaccine in children of 2-3 and 7-8 years of age, Vaccine 18 (15) (2000) 1456-1466.
49. Decker M.D., Edwards K.M., The multicenter acellular pertussis trial. An overview, J. Infect. Dis, 174 (Suppl. 3) (1996) S270-S275.
50. Del Giudice G., Ghiara P., Rappuoli R., Experimental model of Helicobacter pylori infection, Ital. J. Gastroenterol. Hepatol. 30 (Suppl. 3) (1998) S261-3263.
51. Eko F.O., Witte A., Huter V., Kuen B., F, st-Ladani S., Haslberger A. et al., New strategies for combination vaccines based on the extended recombinant bacterial ghost system, Vaccine 17 (13-14) (1999) 1643-1649.
52. Eldridge J., Gilley R., Staats J.. Moldaveanu Z.. Meulbroek J., Tice T., Biodegradable microspheres: Vaccine delivery system for oral immunization, Curr. Top, Microbiol. Immunol. 146 (1989) 59-66.
53. Ellis R.W., New technologies for making vaccines, Vaccine 17 (13-14) (1999) 1596-1604.
54. Ellis R.W., Development of combination vaccines, Vaccine 17 (13-14) (1999) 1635-1642.
55. Ernst J.D., Toward the development of anti-bacterial vaccines; report of a symposium and workshop, Organizing Committee, Clin. Infect. Dis. 29 (5) (1999) 1295-1302.
56. Eskola J., Anttila M., Pneumococcal conjugate vaccines, Pediatr. Infect. Dis. J. 18 (6) (1999) 543-551.
57. Faro J., Seoane R., Eiras A., Lareo I., Couceiro J., Regueiro B.J., Immunoresponses to Neisseria meningitidis epitopes: Suppression of secondary response to phosphorylcholin is carrier specific, Infect. Immun. 51 (1) (1998) 224-232.
58. Fattom A.I., Sarwar J., Ortiz A.. Naso R., A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge, Infect. Immun. 64 (5) (1996) 1659-1665.
59. Feder H.M., Beran J., van Hoecke C., Abraham B., de Clercq N., Buscarino C., Parenti D.L, Immunogenicity of a recombinant Borrelia burg dorferi outer surface protein A vaccine against Lyme disease in children, J. Pediatr. 135 (5) (1999) 575-579.
60. Feldman C., Klugman K., Pneumococcal infections, Curr. Opin. Infect. Dis, 10 (1997) 109-115.
61. Fine P.E.M., Clarkson J.A., Reflections on the efficacity of pertussis vaccines, Rev. Infect. Dis. 9 (5) (1987) 866-883.
62. Finke M., Duchéne M., Eckhardt A., Domdey H., von Specht B.U., Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Eschefichia coli, Infect. Immun. 58 (7) (1990) 2241-2244.
63. Fischer R.T., Longo D.L., Kenny J.J.. A novel phosphorylcholine antigen ptotects both normal and X-linked immune deficien mice against Streptococcus pneumoniae, J. Immunol. 154 (7) (1995) 3373-3382.
64. Flock J.I., Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections, Mol. Med. Today 5 (12) (1999) 532-537.
65. Fusakawa L.O., Gorla M.C., Schenkman R.P., Garcia L.R., Carneiro S.M., Raw I., Tanizaki M.M., Noisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate, Vaccine 17 (23-24) (1999) 2951-2958.
66. Gale J.L.,Japa P.B., Wassilak S.G., Bobo J.K., Mendelman P.M., Foy H.M., Risk of serious acute neurological illness after immunization with diphteria-tetanus-pertussis vaccine. A population-based case-control study, JAMA 271 (1) (1994) 37-41.
67. Garpenholt O., Silfverdal S.A., Hugosson S., Fredlund H., Bodin L., Romanus V., Olcen P., The impact of Haemophilus influenzae type b vaccination in Sweden, Scand. J. Infect. Dis. 28 (2) (1996) 165-169.
68. Ghiara P., Rossi M., Marchetti M., Di Tommaso A., Vindigni C., Ciampolini F. et al., Therapeutic intragastric vaccination againt H. pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection, Infect, Immun. 65 (12) (1997) 4996-5002.
69. Gilleland H.E., Parker M.G., Mathews J.M., Berg R.D., Use of purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice, Infect. Immun. 44 (1) (1984) 49-54.
70. Gillespie S., Ainscough S., Dickens A., Lewin J., Phosphorylcholine-containing antigens in bacteria from the mouth and respiratory tract, J. Med. Microb. 44 (1) (1996) 35-40.
71. Goldblatt D., Conjugate vaccines, Clin. Exp. Immunol. 119 (1) (2000) 1-3.
72. Gravekamp C., Kasper D.L., Paoletti, U.C., Madoff L.C., Alpha C protein as a carrier tor type III capsular polysaccharide and as protective protein in group B streptococcal vaccines, Infect. Immun. 67 (5) (1999) 2491-2496.
73. Griffin M.R., Ray W.A., Mortimer E.A., Fenickel G.M., Schaffner W., Risk of seizures and encephalopathy affer immunization with DTP vaccine, JAMA 263 (12) (1990) 1641-1645.
74. Grimpel E., Les vaccins coquelucheux, Med. Ther. 6 (4) (2000) 274-279.
75. Guiso N., Diagnostic biologique de la coqueluche, Rev, Mal. Respir. 13 (6) (1996) 611-613.
76. Gupta R.K., Taylor D.N., Bryla D.A., Robbins J.B., Szu S.C., Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers, Infect. Immun. 66 (7) (1998) 3095-3099.
77. Guzman C.A., Talay S.R., Molinari G., Medina E., Chatwai G.S., Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein Sfbl, J. Infect. Dis. 179 (4) (1999) 901-906.
78. Heath P.T., Haemophilus influenzae type b conjugate vaccines: A review of efficacity data, Pediatr. Infect. Dis. J. 17 (Suppl. 9) (1998) S117-S122.
79. Hewlett E.L., Pertussis: Current concepts of pathogenesis and prevention, Pediatr. Infect. Dis. J. 16 (Suppl. 4) (1997) S78-S84.
80. Huang L.M., Lee C.Y., Lin T.Y., Chen J.M., Lee P.I., Hsu C.Y., Responses to primary and booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age, Vaccine 14 (9) (1996) 916-922.
81. Insel R.A., Anderson P.W., Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants, J. Exp. Med. 163 (2) (1986) 262-269.
82. Isacson J., Trollfors B., Taranger J., Lagergard T., Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis, Pediatr. Infect. Dis. J. 14 (6) (1995) 517-521.
83. Jang I.J., Kim I.S., Park W.J., Yoo K.S., Yim D.S., Kim H.K. et al., Human immun response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 17 (2) (1999) 158-168.
84. Jansen C., Kuipers B., van der Biezen J., de Cock H., van der Ley P., Tommassen J., Immunogenicity of in vivo folded outer membrane protein PorA of Neisseria meningitidis, FEMS Immunol. Wed. Microbiol. 27 (3) (2000) 227-233.
85. Jennings H.J., Capsular polysaccharides as vaccina candidates, Curr. Top. Microbiol. Immunol. 150 (1990) 97-127.
86. Johnson J.A., Joseph, A., Morris J.G., Capsular polysaccharide-protein conjugate vaccines against Vibrio cholerae O139 Bengal, Bull. Inst. Pasteur 93 (4) (1995) 285-290.
87. Kasper D.L, Paoletti L.C., Wessels M.R., Guttormsen H.-K., Carey V., Jennings H.J., Baker C.J., Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine, J. Clin. Invest. 98 (10) (1996) 2308-2314.
88. Kaufmann S.H., Antibacterial vaccines: Impact of antigen handling and immune response, J. Mol. Med. 75 (5) (1997) 360-363.
89. K‰yhty H., hman H., R̂nnberg P.R., Tillikainen R., Escola J., Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenis in infants and children, J. Infect. Dis. 172 (5) (1995) 1273-1278.
90. K‰yhty H., Eskola J., New vaccines for the prevention of pneumococcal infections, Emerg. Infect. Dis. 2 (4) (1996) 289-298.
91. King J.C., Vink P.E., Farley J.J., Parks M., Smilie M., Madore D. et al., Comparison of the safety and immunogenicity of a pneumococoal conjugate with a liscensed polysaccharide vaccine in human immunodeficiency virus and non human immunodeficiency virus-infected children, Pediatr. Infect. Dis. J. 15 (3) (1996) 192-196.
92. Kleanthous H., Myers G.A., Georgakopoulos K.M., Tibbitts T.J., Ingrassia J.W., Gray H.L. et al., Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection, Infect. Immun. 66 (6) (1998) 2879-2886.
93. Klein D.L., Pneumococcal conjugate vaccines: Review and update, Microb. Drug Resist, 1 (1) (1995) 49-58.
94. Klein J., Kùppen A., Lùffelholz K., Schmitthenner J., Uptake and metabolism of choline by rat brain after acute choline administration, J. Neurochem. 58 (3) (1992) 870-876.
95. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N., Immunogenicity, efficacity and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization, Vaccine 14 (5) (1996) 435-438.
96. Knapp B., Hundt E., Lenz U., Hungerer K.D., Gabelsberger J., Domdey H. et al., A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa, Vaccine 17 (13-14) (1999) 1663-1666.
97. Kniskern P.J., Marburg S., Ellis R.W., Haemophilus influenzae type b conjugate vaccines, in: Powell M., Newman M. (Eds.) Vaccine Design: The Subunit Approach, Plenum Publishing Corporation, New York, 1995, pp. 673-694.
98. Kok M., Pechére J.C., Nouvelles stratégies vaccinales antibactériennes, Press. Med, 25 (8) (1996) 337-341.
99. Konadu E., Donohue-Rolfe A., Calderwood S.B., Pozsgay V., Shiloach J., Robbins J.B., Szu S.C., Synthesis and immunologic properties of Escherichia coli O157 O-specific polysaccharide and shiga toxin 1 B subunit conjugates in mice, Infect. Immun. 67 (11) (1999) 6191 6193.
100. Krause R.M., Dynamics of emergence, J. Infect. Dis. 170 (2) (1994) 265-271.
101. Kurstak E., Towards new vaccines and modern vaccinology: Introductory remarks, Vaccine 17 (13-14) (1999) 1583-1586.
102. Langermann S., Mollby R., Burlein J.E., Palaszynski S.R., Auguste C.G., DeFusco A. et al., Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli, J. Infect. Dis. 181 (2) (2000) 774-778.
103. Leach A., Ceesay S.J., Banya W.S., Greenwood B.M., Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants, Pediatr. Infect. Dis. J. 15 (4) (1996) 333-339.
104. Leach A., Tumani B.A., Banya W.S., Jaffar S., Forrest B.D., Granoff D.M. et al., Induction of immunogenic memory in Gambian children by vaccination in infancy with a group A and C meningococcal polysaccharide-protein conjugate vaccine, J. Infect. Dis, 175 (1) (1997) 200-204.
105. Lindberg A.A., Glycoprotein conjugate vaccines, Vaccine 17 (Suppl. 2) (1999) S28-S36.
106. Lipsitch M., Bacterial vaccines and serotype replacement: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae, Emerg. Infect. Dis. 5 (3) (1999) 336-345.
107. Liptak G.S, McConnochie K.M., Roghmann K.J., Panzer J.A., Decline of paediatric admissions with Haemophilus influenzae type b in New York state, 1982 through 1993: Relation to immunizations, J. Pediatr. 130 (6) (1997) 923-930.
108. Lopez A.L., Blumberg D.A., An overview of the status of acellular pertussis vaccines in practice, Drugs 54 (2) (1997) 189-196.
109. Lutwick L.I., Abramson J.M., Pediatric immunization for the future. Lyme disease vaccine and beyond, Pediatr. Clin. North Am. 47 (2) (2000) 465-479.
110. Mansouri E., Gabelsberger J., Knapp B., Hund E., Lenz U., Hungerer K.D. et al., Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-l vaccine in human volunteers, Infect. Immun, 67 (3) (1999) 1461-1470.
111. Marchetti M., Arico B., Burroni D., Figura N., Rapuolli R., Ghiara P., Development of a mouse model of Helicobacter pylori infection that mimics human disease, Science 267 (5204) (1995) 1655-1658.
112. Marchetti M., Rossi M., Giannelli V., Guliani M.M., Pizza M., Censini S. et al., Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant, Vaccine 16 (1) (1998) 33-37.
113. Matthews-Greer J.M., Gilleland H.E., Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model, J. Infect. Dis. 155 (6) (1987) 1282-1291.
114. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P., Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180 (4) (1999) 1171-1176.
115. McCool T.L., Harding C.V., Greenspan N.S., Schreiber J.R., B-and T-cell immune responses to pneumococcal conjugate vaccines: Divergence between carrier-and polysaccharide-specific immunogenicity, Infect. Immun. 67 (9) (1999) 4862-4869.
116. McQueen C.E., Boedeker E.C., Reid R., Jarboe M., Wolf M., Le M., Brown W.R., Pili in microspheres protect rabbits from diarrhoea induced by E. coli strain RDEC-1, Vaccine 11 (2) (1993) 201-206.
117. Moreau M., Un nouveau concept vaccinal : Les vaccins polyosides conjugués, Ann. Pharm. Fr. 57 (3) (1999) 223-231.
118. M,hlemann K., Alexander E.R., Pepe M., Weiss N.S., Schopfer K., Invasive Haemophilus influenzae disease and epiglottitis among swiss children from 1980 to 1993, Evidence for herd immunity among older age groups, Scand. J. Infect. Dis. 28 (3) (1996) 265-268.
119. Musher D.M., infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity and treatment, Clin. Infect. Dis. 14 (4) (1992) 801-009.
120. Mutharia L.M., Nicas T.I., Hancock R.E.W., Outer membrane proteins of P. aeruginosa serotype strains, J. Infect. Dis. 146 (6) (1982) 770-779.
121. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., Wurtman R.J., Evidence for a membrane defect in Alzheimer disease brain, Pro. Natl. Acad. Sci. USA 89 (5) (1992) 1671-1675.
122. O'Hagan D.T., McGee J.P., Holmgren J., Mowat A.. Donachie AM.. Mills K.H.G., Gaistord W., Rahman D., Challacombe S.J., Biodegradable microparticles for oral immunization. Vaccine 11 (2) (1993) 149-154.
123. Paoletti L.C., Pinel J., Johnson K.D., Reinap B., Ross R.A., Kasper D.L., Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. J. Infect. Dis. 180 (3) (1999) 892-895.
124. Park H.M., Yoo H.S., Oh T.H., Kim D., Han H.R., Immunogenicity of alpha-toxin, capsular polysaccharide (CPS) and recombinant fibronectin-binding protein (r-FnBP) of Staphylococcus aureus in rabbit, J. Vet. Med. Sci. 61 (9) (1999) 995-1000.
125. Paton J.C., Andrew W., Boulnois G.J., Mitchell T.J., Molecular analysis of the pathogenicity of Streptococcus pneumoniae, the role of pneumococcal proteins, Annu. Rev. Microbiol. 47 (1993) 89-115.
126. Pecquet S., Ehrat C., Ernst P.B., Enhancement of mucosal antibody responses to Salmonella typhimurium and the microbial hapten phosphorylcholine in mice with X-linked immunodeficiency by B-cell precursors from the peritoneal cavity, Infect. Immun. 60 (2) (1992) 503-509.
127. Peeters C.C.A.M., Tenbergen-Meekes A.M., Evenberg D.E., Poolman J.T., Zegers B.J.M., Rijkers G.T., A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice, J. Immunol. 146 (12) (1991) 4308-4314.
128. Peeters C.C., Claassen I.I., Schuller M., Kersten G.F., van der Voort EM., Poolman J.T., Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice, Vaccine 17 (20-21) (1999) 2702-2712.
129. Peltola H., Kilpi T., Anttila M., Rapid disappearance of Haemophilus influenzae type b meningitidis after routine chilhood immunisation with conjugate vaccines, Lancet 340 (8819) (1992) 592-594.
130. Peltola H., Haemophilus influenzae type b disease and vaccination in Europe: Lessons learned, Pediatr. Infect. Dial. J. 17 (Suppl. 9) (1998) S126-S132.
131. Philipp M.T., Lobet Y., Bohm R.P., Roberts E.D., Dennis V.A., Gu Y. et al., The outer surface protein A (OspA) vaccine against Lyme disease: Efficacy in the rhesus monkey, Vaccine 15 (17-18) (1997) 1872-1887.
132. Pichichero M.E.. Shelly M.A, Treanor J.J., Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers, Pediatr. Infect. Dis. J. 16 (1) (1997) 72-74.
133. Pines E., Barrand M., Fabre P., Salomon H., Blondeau C., Wood S.C., Hoffenbach A., New acellular pertussis-containing paediatric combined vaccines, Vaccine 17 (13-14) (1999) 1650-1656.
134. Pittman M., Pertussis toxin: The cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis, Rev. Infect. Dis. 1 (3) (1979) 401-412.
135. Plotkin S.A., Cadoz M., The acellular pertussis vaccine trials: An interpretation, Pediatr. Infect. Dis. J. 16 (5) (1997) 508-517.
136. Poland G.A., The burden of pneumococcal disease: The role of conjugate vaccines, Vaccine 17 (13-14) (1999) 1674-1679.
137. Pollock Y.M., Morris J., A 7-year survey of disorders attributed to vaccination in north West Thames region, Lancet 1 (8327) (1983) 753-757.
138. Reinert P., Vaccins sous-unités polysaccharidiques, Rev. Prat. 45 (12) (1995) 1484-1487.
139. Reinert P., Leroux M.C., Boucher J., Eradication des méningites à Haemophilus influenzae b dans le département du Val-de Marne, Med. Mal. Infect. 27 (1997) 505-506.
140. Reinert P., Les vaccins pneumococciques conjugués. Arch. Pediatr. 6 (Suppl. 3) (1999) S643-S646.
141. Richmond P., Goldblatt D., Fusco P.C., Fusco J.D. Heron I., Clark S. et al., Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults, Vaccine 18 (7-8) (1999) 641-546.
142. Risberg A., Schweda E., Jansson P., Structural studies of the cell-envelope oligosaccharide from lipopolysaccharide of Haemophilus influenzae strain RM 118-28, Eur. J. Biochem. 243 (3) (1998) 701-707.
143. Robbins J.B., Scheerson R., Polysaccharide-protein conjugates: A new generation of vaccines, J. Infect. Dis. 161 (1990) 821-832.
144. Romanus V., Jonsell R., Berquest S.O., Pertussis in Sweden after the cessation of general immunization in 1979, Pediatr. Infect. Dis. J. 6 (4) (1987) 364-371.
145. Sansonetti P.J., Prevention des maladies diarrheiques et vaccination orale, Rev. Prat, 45 (12) (1995) 1512-1513.
146. Sepp‰l‰ I., Sarvas H., M‰kel‰ O., Mattila P., Eskola J., K‰yhty H., Human antibody responses to two conjugate vaccines of Haemophilus influenzae type b saccharides and diphteria toxin, Scand. J. Immunol. 28 (4) (1988) 471-479.
147. Shahin R.D., Amsbaugh D.F., Leef M.F., Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection, Infect. Immun. 60 (4) (1992) 1482-1488.
148. Shahin R., Leef M., Eldridge J., Hudson M., Gilley R., Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-Lactide-co-glycolide) microspheres, Infect. Immun. 63 (4) (1995) 1195-1200.
149. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B. et al., Safety and immunogenicity of heptavalent pneurmococcal CRM197 conjugate vacine in infants and toolers, Pediatr. Infect. Dis. J. 18 (9) (1999) 757-763.
150. Singh M., Ganguly N.K., Kumar L., Vohra H., Protective efficacity and immunogenicity of Vi-porin conjugate against Salmonella typhi, Microbiol. Immunol. 43 (6) (1999) 535-542.
151. Stein K.E., Thymus-independent and thymus-dependent responses to polysaccharide antigens, J. Infect. Dis. 165 (Suppl. 1) (1992) S49-S52.
152. Steinhoff M.C., Edwards K., Keyserling H., Thorns M.L., Johnson C., Madore D., Hogerman D., A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: Effect of polysaccharide size and linkage characteristics, Pediatr. Infect. Dis. J. 13 (5) (1994) 368-372.
153. Takala A.K., Escola J., Lievonen M., Käyhty H., Nissinen A., Pekkanen E., Makela P.H., Reduction of oropharyngeal carriage of the Haemophilus inflenzae type b (Hib) disease in children immunised with an Hib conjugate vaccine, J. infect. Dis. 154 (5) (1991) 982-986.
154. Taylor D.N., Trota A.C., Sadoff J., Chu C., Bryla D., Skiloach J. et al., Synthesis, characterization and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids, Infect Immun. 61 (9) (1993) 3678-3687.
155. Thanassi W.T., Schoen R.T., The lyme disease vaccine: Conception, development, and implementation, Ann. Intern. Med. 132 (18) (2000) 661-668.
156. Tomasz A., Choline in the cell wall of a bacterium: Novel type of polymer-linked choline in pneumococcus, Science 157 (789) (1967) 694-697.
157. Trollé S., Andremont A., Fattal E. Towards a multipurpose mucosal vaccination using phosphorylcholine as a unique antigen? STP Pharma. Sciences 8 (1) (1998) 19-30.
158. Trollé S., Caudron E., Leo E., Couvreur P., Andremont A., Fattal E., In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin, Int. J. Pharm. 183 (1) (1999) 73-79.
159. Trollé S., Chachaty E., Kassis-Chikhani N., Wang C., Fattal E., Couvreur P. et al., Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumoniae, Vaccine (2000) (à paraître).
160. Tron F.. Immunologie de la vaccination, Rev. Prat. 45 (12) (1995) 1478-1483.
161. Tron F., Les vaccins du futur. Rev. Prat. 45 (12) (1995) 1514-1519.
162. Vogel F.R., Nucleic acid vaccines. Clin. Microbiol. Rev. 8 (3) (1995) 406-410.
163. von Specht B.U., Knapp B., Muth G., Br̂ker M., Hungerer K.D., Diehl K.D. et al., Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein l fusion proteins, Infect. Immun. 63 (5) (1995) 1855-1862.
164. von Specht B.U.. L,cking C., Blum B., Schmitt A., Hungerer K.D., Domdey H., Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein l vaccine in human volunteers, Vaccine 14 (12) (1996) 1111-1117.
165. von Specht B.U.. Knapp B., Hungerer K.D., L,cking C., Schmitt A., Domdey H., Outer membrane proteins of Pseudornonas aeruginosa as vaccine candidates, J. Biotech. 44 (1-3) (1996) 145-153.
166. Wahlberg P., Vaccination against Lyme borreliosis, Ann. Med. 31 (4) (1999) 233-235.
167. Weiser J.N., Shchepetov M, Chong S.T., Decoration of lipopolysaccharide with phosphorylcholine: A phase-variable characteristic of Haemophilus influenzae, Infect. Immun. 65 (3) (1997) 943-950.
168. Weiser J.N., Pan N., McGowan K.L., Musher D., Martin A., Richards J., Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein, J. Exp. Med. 187 (4) (199B) 631-640.
169. Weiser J.N., Goldberg J.B., Pan N., Wilson L., Virji M., The phosphorylcholine epilope undergoes variation on a 43-kilodalton protein in Pseudomonas aeruginosa and on pili of Neisseria meningitidis and Neisseria gonorrhoeae, Infect. Immun. 66 (9) (1998) 4263-4267.
170. Wenger J.D., Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae conjugate vaccines in the United States and Canada, Pediatr. Infect. Dis. J. 17 (Suppl. 9) (1998) S132-S136.
171. Whitton J.L., Rodriguez F., Zhang J., Hassett D.E., DNA immunization: Mechanistic studies, Vaccine 17 (13-14) (1999) 1612-1619.
172. Wilske B., Bush U., Fingerle V., Jauris-Heipe S., Preac Mursic V., Rossler D., Will G., Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development, Infection 24 (2) (1996) 208-212.
173. Wizemann T.M., Adamou J.E., Langermann S., Adhesins as targets for vaccine development, Emerg. Infect. Dis. 5 (3) (1999) 395-403.
174. Zhong W., Stehle T., Museteanu C., Siebers A., Gern L., Kramer M. et al., Therapeutic passive vaccination against chronic Lyme disease in mice, Proc. Natl. Acad. Sci. USA 94 (23) (1997) 12533-1253B.